Clinical status of agents being developed for leishmaniasis
about
Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanismControl of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements.Gene disruption of the DNA topoisomerase IB small subunit induces a non-viable phenotype in the hemoflagellate Leishmania majorIs paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.Identification of novel inhibitors of dipeptidylcarboxypeptidase of Leishmania donovani via ligand-based virtual screening and biological evaluation.Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.Treatment options for visceral leishmaniasis.In Vitro and In Vivo Antileishmanial Effects of Pistacia khinjuk against Leishmania tropica and Leishmania major.Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samplesAnti-Leishmania Activity of OstholeGlycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.Drug delivery systems for the topical treatment of cutaneous leishmaniasis.Modes of action of Leishmanicidal antimicrobial peptides.Novel approaches for the identification of inhibitors of leishmanial dipeptidylcarboxypeptidase.Interactions of antiparasitic alkaloids with Leishmania protein targets: a molecular docking analysis.Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.Therapeutic efficacy induced by the oral administration of Agaricus blazei Murill against Leishmania amazonensis.
P2860
Q24675578-E5FA22AD-3797-4497-84C2-973D54EE7128Q30565638-DE425338-2D48-4E1F-9029-5A1C8946C696Q33350046-48CABE3A-13F9-41B9-AE70-BF7BFACCA65CQ33409844-99264C95-24DD-49BD-A0CF-6303A15CBBDAQ34052442-86E18968-B514-4203-B982-3600787BDC25Q34289958-987F53EC-F3B0-4EE4-B04D-555F77817DC7Q34510966-07B464D4-C295-4D44-9BB8-EEFDA2D16C15Q35178150-1BF62DCD-E0C7-4A33-BEAB-3519DA15F890Q35530589-6DE9D264-2E26-4F7A-AD7B-937DE5F94586Q36766144-A6E6C952-50C5-4AF0-BD8E-396E58DFA74AQ37763950-20A3E9E0-B9A9-4310-83A2-053A4C000CD1Q38020882-E69DFBB0-BA05-4AA0-9C47-224AEA3E69C4Q38041188-2E20624E-9507-4DA9-98F3-3D63204C9ECCQ38112776-DB0A41F3-F2A1-4E61-B4DA-4A6FA200C4B6Q39328997-DB60C970-CA59-41C0-BEE2-F0BCA135A7ADQ41011525-593871DD-CC02-4690-8ED1-9A58424842DEQ41844113-A596A5B7-BAEA-4AE6-BB9A-A8555C399E9CQ46054491-4B39FC24-872C-42DB-92DA-E09B00D09B89
P2860
Clinical status of agents being developed for leishmaniasis
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Clinical status of agents being developed for leishmaniasis
@ast
Clinical status of agents being developed for leishmaniasis
@en
Clinical status of agents being developed for leishmaniasis
@nl
type
label
Clinical status of agents being developed for leishmaniasis
@ast
Clinical status of agents being developed for leishmaniasis
@en
Clinical status of agents being developed for leishmaniasis
@nl
prefLabel
Clinical status of agents being developed for leishmaniasis
@ast
Clinical status of agents being developed for leishmaniasis
@en
Clinical status of agents being developed for leishmaniasis
@nl
P2860
P1476
Clinical status of agents being developed for leishmaniasis
@en
P2093
Jonathan Berman
P2860
P304
P356
10.1517/13543784.14.11.1337
P407
P577
2005-11-01T00:00:00Z